Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Viltolarsen in Duchenne Muscular Dystrophy (VILT-502)
NCT04687020Phase 4Active, not recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Jun 2021
- Primary completion
- Sep 2032
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of viltolarsen in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc. Primary endpoints: Number of participants with treatment related Adverse Events at 120 months, Change in Time to Stand at 120 months and 3 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04687020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687020.